ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein
29 août 2019 07h40 HE
|
ChemioCare
NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the addition of Dr....
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
15 juil. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
14 mai 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
29 avr. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
14 nov. 2018 08h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
01 nov. 2018 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to...
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
18 avr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...
Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting
11 avr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- In vivo data to be presented via poster highlighting the ability of Actinium’s AWE Technology to yield increased cell killing power, survival benefit and a potential biobetter of daratumumab, a...
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
28 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
08 févr. 2018 08h00 HE
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...